NSE: AUROPHARMA | BSE: 524804

Mid-range Performer

Download real time

1162.20 4.20 (0.36%)

27.00% Fall from 52W High

368.3K NSE+BSE Volume

NSE 31 Jul, 2025 9:32 AM (IST)

67,500.8

Market Cap

High in industry

0.9

Beta 1Year

Low volatility

Board Meeting

The next board meeting for Aurobindo Pharma Ltd. is on 04 Aug 2025 for the purpose of Quarterly Results & Interim Dividend See details

Aurobindo Pharma Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for AUROPHARMA, BSE:524804 Aurobindo Pharma Ltd.

Aurobindo Pharma Ltd.

07 Sep 2018

1162.20

0.36%

Company Updates

Buy: Aurobindo Pharma Ltd.

Target

Angel Broking

Aurobindo Pharmaceuticals (APL) has acquired dermatology and oral solids businesses from Sandoz Inc., USA for an upfront purchase price of US$0.9bn in cash. With this acquisition, Aurobindo adds sales of US$0.9bn and would become the 2nd largest generic player in the US by number of prescriptions. Acquisition is funded by debt and values ..

Aurobindo Pharma Ltd. is trading above its 100 day SMA of 1155.1

Aurobindo Pharma Ltd.

07 Sep 2018

1162.20

0.36%

Aurobindo Pharma Limited

Buy: Aurobindo Pharma Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Aurobindo has entered into an agreement with US based Sandoz Inc. (generics / biosimilars arm of Novartis AG) to acquire its US Dermatology and Oral solid businesses for a consideration of US$ 900 million. Acquired portfolio comprises of 1) Portfolio of dermatology and oral solids, 2) authorised generics and in-licensed products, branded dermatology products (~US$ 50 million), 3) three manufacturing facilities at Hicksville - NY (Derma), Melville NY (Derma) and Wilson- NC (OSD)...

Aurobindo Pharma Ltd. is trading below its 150 day SMA of 1166.1

Aurobindo Pharma Ltd.

06 Sep 2018

1162.20

0.36%

Sandoz deal at attractive valuation

Buy: Aurobindo Pharma Ltd.

Target

Motilal Oswal

6 September 2018 a definitive agreement with Sandoz, USA to acquire its dermatology and oral solids businesses. The upfront purchase price is USD900m in cash, which includes a potential upside in near-term earn-out and additional potential earn-out on pipeline products in outer years. The portfolio to be acquired has a revenue contribution of 70% from oral solids and 30% from dermatology. ARBP guided for sales of USD900m in the first 12 months after the closure of transaction, adjusting for the expiration of certain in-licensed product contracts and the rationalization of the acquired products. acquisition will add ~300 products, including those that are already commercialized and also the ones that are yet to be approved. The deal also adds two derma- dedicated manufacturing facilities (including dermatology dedicated R&D; facility) in the US. The sales guidance of USD900m on a 12-month basis post the closure of transaction and the EBITDA margin guidance of ~22-23% imply an EBITDA of ~USD198m.

Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings

Aurobindo Pharma Ltd.

14 Aug 2018

1162.20

0.36%

Aurobindo Pharma Ltd. - Result Update - 14 August 2018

Buy: Aurobindo Pharma Ltd.

Way2Wealth

Aurobindo Pharma consolidated revenue from operation grew 15.5% on a YoY basis to `4250.27 Crs. in Q1. Growth has been aided by API segment, US, and Europe formulation business segments. However, the ARV business contracted 36% on YoY basis due to weak...

Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings

Aurobindo Pharma Ltd.

13 Aug 2018

1162.20

0.36%

Aurobindo Pharm

Buy: Aurobindo Pharma Ltd.

Target

Centrum Broking

We maintain our Buy rating on Aurobindo Pharma (APL) and revise TP to Rs1,010 (earlier Rs1,070) based on 18x March'20E EPS of Rs56.2. The company's Q1FY19 revenue was in-line with our expectations. However, EBIDTA margin and net profit were below expectation. APL's sales grew 16% YoY, margin declined 460bps to 18.3% and net profit declined by 12% YoY. Its specialised segments such as injectables, penam, microspheres, hormones, oncology, vaccines, neutraceutical, depot injections, OTC and peptides would improve margins due to complexity in the manufacturing. APL has developed a robust pipeline of 487 ANDAs for the US...

Aurobindo Pharma Ltd. is trading above its 100 day SMA of 1155.1

Aurobindo Pharma Ltd.

11 Aug 2018

1162.20

0.36%

Aurobindo Pharma (1QFY19): Reslient performance. Maintain BUY

Buy: Aurobindo Pharma Ltd.

Target

HDFC Securities

Maintain BUY rating, with a revised TP of Rs 691 (16x FY20E). Aurobindo Pharmas (ARBP) revenue in 1QFY19 came in at Rs 4.6bn, up 16.7%YoY and 5%QoQ, beating our estimates by 8%. This was aided by good double-digit growth in the formulations segment, with US and Europe/RoW growing at 11.5% and 31% YoY respectively. Gross margin dropped to 55% (v/s 59% in 1QFY18) due to one-off inventory provisions and shelf stock adjustment.

Aurobindo Pharma Ltd. is trading below its 150 day SMA of 1166.1

Aurobindo Pharma Ltd.

10 Aug 2018

1162.20

0.36%

Aurobindo Pharma Limited

Buy: Aurobindo Pharma Ltd.

Recommendation Target

ICICI Securities Limited

After filing ANDA in the US in 2003, the company has come a long way as current ANDA filings are at 487. The US revenue run rate has grown from ~US$100 million in 2009 crossing $1 billion sales as on 2017. Note that this was despite the USFDA embargo in FY12-13 on unit VI and unit III. In rupee term, US sales have grown at 34% CAGR to | 7442 crore in FY1318. US formulations now constitute 45% of total turnover, up from 30% in FY13. However, US pricing pressure in the oral solid space (~77% of US sales) is likely to be the main stumbling block for growth. We expect US FY20E sales to grow at 8.4% CAGR to | 8758 crore in FY18-20E on the back of...

Promoters pledged 0.16% of shares in last quarter. Total pledge stands at 17.08% of promoter holdings

Aurobindo Pharma Ltd.

10 Aug 2018

1162.20

0.36%

Result Updates

Buy: Aurobindo Pharma Ltd.

Target

Angel Broking

For 1QFY2019, Aurobindo Pharma (APL) posted decent set of numbers on topline. On sales front, the company posted sales of `4,182cr v/s. `3,621cr in 1QFY2018, a yoy growth of 15.5%. On the operating front, the EBITDA margin at 17.0% v/s. 21.6% in 1QFY2018.Consequently, the Adj. PAT came in at `456cr v/s. `518cr in 1QFY2018, a yoy de-growth..

Aurobindo Pharma Ltd. has an average target of 1461.67 from 9 brokers.

Is Aurobindo Pharma Ltd. worth buying?

1250 Votes:

Buy 80.16%

Sell 13.84%

Hold 6.0%

RESEARCH REPORTS

Buy SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf